VOLPARA HEALTH TECHNOLOGIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.145 AUD | +0.44% |
|
0.00% | +3.62% |
| May. 06 | Volpara Health Technologies Limited(ASX:VHT) dropped from S&P/ASX Emerging Companies Index | CI |
| May. 03 | Volpara to Delist After Court Approves Acquisition by Lunit | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.62% | 193M | - | ||
| +5.98% | 33.18B | C | ||
| +21.35% | 7.81B | C- | ||
| +25.15% | 3.98B | B- | ||
| -17.74% | 3.17B | C- | ||
| -20.49% | 1.39B | B | ||
| -30.40% | 1.2B | - | ||
| +7.49% | 970M | C | ||
| -34.66% | 950M | - | ||
| -27.55% | 808M | - | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VHT Stock
- Ratings Volpara Health Technologies Limited